Back to Results
First PageMeta Content
Olaparib / Primary peritoneal carcinoma / Ovarian cancer / BRCA mutation / Fallopian tube cancer / PARP1 / Serous carcinoma / PARP inhibitor / Breast cancer / Medicine / Oncology / Gynaecological cancer


MSAC Application 1380 Germline BRCA mutation testing to determine eligibility for olaparib maintenance therapy in women with platinum-sensitive relapsed ovarian cancer (including fallopian tube or primary peritoneal canc
Add to Reading List

Document Date: 2014-12-15 23:44:34

Open Document

File Size: 663,68 KB

Share Result on Facebook

Company

ADP / Gynecological Cancer InterGroup / /

Country

Australia / /

Event

FDA Phase / /

Facility

harbour TP53 / The complex / /

IndustryTerm

machinery / proposed medical services / therapy for women who have PSR ovarian cancer / /

MedicalCondition

Epithelial ovarian carcinoma / Ovarian cancer Ovarian cancer / cancers / ovarian cancers / hereditary susceptibility / ovarian cancer / BRCA-related cancers / cancer / platinum-sensitive relapsed ovarian cancer / fallopian tube cancer / disease / PSR ovarian cancer / carcinomas / invasive epithelial ovarian cancer / tumour / primary peritoneal cancer / carcinoma / tumours / /

MedicalTreatment

chemotherapy / surgery / counselling / /

Organization

Medicare / /

Product

carboplatin / adenosine / paclitaxel / NCT00753545 / /

Technology

genotyping / recombination / high grade serous component Applicant Submitted Proposed Protocol / chemotherapy / /

URL

http /

SocialTag